Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis

Psychoneuroendocrinology

Volumn 63, Issue , 2016, Pages 144-154

  Stubbs, Brendon ^a,b   Wang, Alexandre K ^c   Vancampfort, Davy ^d   Miller, Brian J ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Leptin; Meta analysis; Metabolism; Obesity; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEPTIN; NEUROLEPTIC AGENT; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

AGE DISTRIBUTION; BODY MASS; BRIEF PSYCHOTIC DISORDER; DISEASE DURATION; GEOGRAPHIC DISTRIBUTION; HORMONE BLOOD LEVEL; HUMAN; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEX DIFFERENCE; SMOKING HABIT; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; MALE; META ANALYSIS; TIME FACTOR;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEPTIN; MALE; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS;

EID: 84949764897     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.09.026     Document Type: Review

References (52)

1. Ak M., Sezlev D., Sutcigil L., Akarsu S., Ozgen F., Yanik T. The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy. Psychoneuroendocrinology 2013, 38:341-347.
2. Arranz B., Rosel P., Ramírez N., Dueñas R., Fernández P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65:1335-1342.
3. American Psychiatric Association, A.P Diagnostic and Statistical Manual of Mental Disorders-DSM-IV-TR 2000, American Psychiatric Association. 4th ed.
4. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr. Scand. 2003, 108:208-214.
5. Bak M., Fransen A., Janssen J., van Os J., Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014, 9:1-19.
6. Basoglu C., Oner O., Gunes C., Semiz U.B., Ates A.M., Ebrinc S., Cetin M., Ozcan O., Ipcioglu O. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int. Clin. Psychopharmacol. 2010, 25:165-171.
7. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
8. Beumer W., Drexhage R.C., De Wit H., Versnel M.A., Drexhage H.A., Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012, 37:1901-1911.
9. Carrizo E., Fernández V., Quintero J., Connell L., Rodrïguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr. Res. 2008, 103:83-93.
10. Correll C.U., Detraux J., De Lepeleire J., De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry: Off. J. World Psychiatr. Assoc. (WPA) 2015, 14:119-136.
11. Cortés B., Bécker J., Mories Álvarez M.T., Marcos A.I., Molina V. Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia. Psychiatry Clin. Neurosci. 2014, 68:127-132.
12. Ebdrup B.H., Knop F.K., Madsen A., Mortensen H.B., Søgaard B., Holst J.J., Szecsi P.B., Lublin H. Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. J. Clin. Psychiatry 2014, 75:e899-e905.
13. Ebenbichler C., Laimer M., Kranebitter M., Lechleitner M., Patsch J.R., Baumgartner S., Edlinger M., Hofer A., Hummer M., Rettenbacher M.A., Fleischhacker W.W. Letter to the editors: the soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr. Res. 2005, 75:143-146.
14. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ Clin. Res. Ed. 1997, 315:629-634.
15. Esen-Danaci A., Sarandöl A., Taneli F., Yurtsever F., Özlen N. Effects of second generation antipsychotics on leptin and ghrelin. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32:1434-1438.
16. Graham K.A., Cho H., Brownley K.A., Harp J.B. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr. Res. 2008, 101:287-294.
17. Haupt D.W., Luber A., Maeda J., Melson A.K., Schweiger J.A., Newcomer J.W. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2005, 30:184-191.
18. Hellström L., Wahrenberg H., Hruska K., Reynisdottir S., Arner P. Mechanisms behind gender differences in circulating leptin levels. J. Intern. Med. 2000, 247:457-462.
19. Herráan A., García-Unzueta M.T., Amado J.A., de la Maza M.T., Álvarez C., Vázquez- Barquero J.L. Effects of long-term treatment with antipsychotics on serum leptin levels. Br. J. Psychiatry 2001, 179:59-62.
20. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ Clin. Res. Ed. 2003, 327:557-560.
21. Hommel J.D., Trinko R., Sears R.M., Georgescu D., Liu Z.-W., Gao X.-B., Thurmon J.J., Marinelli M., DiLeone R.J. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006, 51:801-810.
22. Hsuan Chi W., Po See C., Lee I.H., Tzung Lieh Y., Ru Band L. Increased plasma leptin in sntipsychotic-naïve females with schizophrenia, but not in males. Neuropsychobiology 2007, 56:213-215.
23. Hägg S., Söderberg S., Ahrén B., Olsson T., Mjörndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J. Clin. Psychiatry 2001, 62:843-848.
24. Jow G.-M., Yang T.-T., Chen C.-L. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J. Affect. Disord. 2006, 90:21-27.
25. Konarzewska B., Stefańska E., Wendołowicz A., Cwalina U., Golonko A., Małus A., Kowzan U., Szulc A., Rudzki L., Ostrowska L. Visceral obesity in normal-weight patients suffering from chronic schizophrenia. BMC Psychiatry 2014, 14:1-21.
26. Leinninger G.M., Jo Y.H., Leshan R.L., Louis G.W., Yang H., Barrera J.G., Wilson H., Opland D.M., Faouzi M.A., Gong Y., Jones J.C., Rhodes C.J., Chua S., Diano S., Horvath T.L., Seeley R.J., Becker J.B., Münzberg H., Myers M.G. Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding. Cell Metabol. 2009, 10:89-98.
27. Lin X., Zhang X., Guo J., Roberts C.K., McKenzie S., Wu W.-C., Liu S., Song Y. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 2015, 4.
28. Lu M.-L., Wang T.-N., Lin T.-Y., Shao W.-C., Chang S.-H., Chou J.-Y., Ho Y.-F., Liao Y.-T., Chen V.C.-H. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 58:47-50.
29. Tsai Meng-Chang, Chang Cia-Ming, Liu Chia-Yih, Chang Pi-Yueh, Huang Tiao-Li Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. Int. J. Psychiatry Clin. Pract. 2011, 15:106-111.
30. Mitchell A.J., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39:295-305.
31. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Clin. Trials 2009, 6:1-6.
32. Murashita M., Inoue T., Kusumi I., Nakagawa S., Itoh K., Tanaka T., Izumi T., Hosoda H., Kangawa K., Koyama T. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin. Neurosci. 2007, 61:54-58.
33. Neamat- Allah J., Wald D., Hüsing A., Teucher B., Wendt A., Delorme S., Dinkel J., Vigl M., Bergmann M.M., Feller S., Hierholzer J., Boeing H., Kaaks R. Validation of anthropometric indices of adiposity against whole-body magnetic resonance imaging-a study within the German European Prospective Investigation into Cancer and Nutrition (EPIC) Cohorts. PLoS One 2014, 9:1-9.
34. Neelamekam S., Nurjono M., Lee J. Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis. Clin. Psychopharmacol. Neurosci. 2014, 12:209-214.
35. Nurjono M., Neelamekam S., Lee J. Serum leptin and its relationship with psychopathology in schizophrenia. Psychoneuroendocrinology 2014, 50:149-154.
36. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., Popovic S., Miljic N., Djurovic M., Jasovic- Gasic M., Dieguez C., Casanueva F.F. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
37. Potvin S., Zhornitsky S., Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can. J. Psychiatry Revnue Can. De Psychiatr. 2015, 60:S26-S34.
38. Schautz B., Later W., Heller M., Peters A., Müller M.J., Bosy-Westphal A. Impact of age on leptin and adiponectin independent of adiposity. Br. J. Nutr. 2012, 108:363-370.
39. Sentissi O., Epelbaum J., Olié J.-P., Poirier M.-F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr. Bull. 2008, 34:1189-1199.
40. Sirota P., Hadi E., Djaldetti M., Bessler H. Difference in inflammatory cytokine production by mononuclear cells from obese and non-obese schizophrenic patients. Acta Psychaitr. Scand. 2000, 132:301-305.
41. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting meta-analysis of observational studies in Epidemiology (MOOSE) group. JAMA: J. Am. Med. Assoc. 2000, 283:2008-2012.
42. Stubbs B., Vancampfort D., De Hert M., Mitchell A.J. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr. Scand. 2015, 132(August (2)):144-157.
43. Sugai T., Suzuki Y., Fukui N., Ono S., Watanabe J., Tsuneyama N., Someya T. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. J. Clin. Psychopharmacol. 2012, 32:390-393.
44. Trujillo M.E., Sullivan S., Harten I., Schneider S.H., Greenberg A.S., Fried S.K. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J. Clin. Endocrinol. Metab. 2004, 89:5577-5582.
45. Urhan M., Ergün C., Aksoy M., Ayer A. Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients. Nord. J. Psychiatry 2015, 69:323-330.
46. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Shetty T.K., Gangadhar B.N. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin. Neuropharmacol. 2010, 33:288-292.
47. Walker E.R., McGee R.E., Druss B.G. Mortality in mental disorders and global disease burden implications: a systematic review andmeta-analysis. JAMA Psychiatry 2015, 72(April (4)):334-341.
48. Wells, G., B. Shea, D. O'Connell, and J. e. a. Peterson, The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (last accessed on 29/09/2015). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
49. Wittert G.A., Turnbull H., Hope P. Exogenously administered leptin leads to weight loss and increased physical activity in the marsupial Sminthopsis crassicaudata. Physiol. Behav. 2005, 85:613-620.
50. Yanik T., Kursungoz C., Sutcigil L., Ak M. Weight gain in risperidone therapy: Investigation of peripheral hypothalamic neurohormone levels in psychotic patients. J. Clin. Psychopharmacol. 2013, 33:608-613.
51. Zhang F., Chen Y., Heiman M., Dimarchi R. Leptin: structure, function and biology. Vitam. Horm. 2005, 71:345-372.
52. Zhang Z.-J., Yao Z.-J., Liu W., Fang Q., Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia. Br. J. Psychiatry 2004, 184:58-62.